# Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

> **NCT02201329** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 5 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Volasertib

## Key facts

- **NCT ID:** NCT02201329
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-01
- **Final completion:** 2015-09
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201329, "Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02201329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*